Benign Prostatic Hyperplasia (BPH) Procedures and its Growth prospect in the Near Future

Increasing life expectancy and fall in the birth rates are the major reasons for rise in the aging population. The people in this category require extensive care, since they are more prone to illness due to low immunity levels and longer recovery time. Increase in the aging population in the U.S., Germany, China and India in the next few years, is expected to create high demand for BPH treatment devices, since the population aged 50 years and above is more prone to BPH, and therefore tend to opt for various treatments that involve the use of procedures such as TURP, prostate implants and laser based treatments. Thus, growing aging population acts as a strong driver supporting the increase in the number of BPH procedures performed.

As per the findings of the research, surgical procedure held the largest share in the global BPH procedures, primarily due to increasing prevalence of BPH disorders. The number of laser based procedure is expected to register fastest growth during the forecast period since these procedures are as effective as surgical procedures and reduce the hospital stay time. Hospitals held the largest share of the number of BPH procedures performed, based on the end user. Ambulatory surgical centers are expected to witness the highest inflow of BPH patients for treatment during the forecast period, due to development of technologically advanced BPH procedures and rising prevalence of BPH disorders leading to the growth in the number of patients treated in the ambulatory surgical centers.

Download Report Sample at: https://www.psmarketresearch.com/market-analysis/benign-prostatic-hyperplasia-procedures/report-sample

Geographically, Europe accounted for the largest number of BPH procedures done in 2016. Growing ageing population, lower cost of BPH treatment as compared to the U.S., high healthcare spending, and technological advancements in the field of urological procedures technology are some of the factors driving the growth of the BPH procedures in the Europe. France, Germany and the U.K. are expected to be the most promising countries for the growth in number of the BPH procedures. In June 2016, National Institute of Health and Care Excellence (NICE) approved GreenLight XPS laser treatment for the treatment of BPH. NICE added that the widespread adoption of the procedure could save the National Health Services (NHS) an estimated $4.3 million (£3 million) a year. Asia-Pacific is expected to witness the high number of BPH procedures performed during the forecast period, owing to the rising prevalence of BPH disorders, increasing disposable income, aging population, and growing efforts to increase awareness about advanced BPH treatment procedures.

Some of the other key players operating in the global BPH procedures include NxThera, Inc., Boston Scientific Corporation, Urologix, LLC., Karl Storz GmbH & Co. KG, Lumenis Ltd., Olympus Corporation, Advin Urology, Convergent Laser Technologies, Richard Wolf GmbH, Medtronic Plc.

Sponsor Ads

• Ad Space Available - Rent it Now!

Report this Page

Created on Aug 8th 2019 02:33. Viewed 357 times.

Share on APSense

Comments